Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

Dow Jones17:19

0919 GMT - Sanofi's incoming CEO Belen Garijo needs to be clear on her strategic priorities, as the French drugmaker still needs to rebuild its drug pipeline, Citi analysts say in a research note. The company aims to defend the exclusivity of its blockbuster anti-inflammatory drug Dupixent--jointly developed with Regeneron--beyond the U.S. compound patent expiration in March 2031, Citi says. It also aims to extend dosing and leverage its alliance with Regeneron to bring new drugs to market, the analysts say. Sanofi has flagged financial firepower of between 15 billion and 25 billion euros for acquisitions and dealmaking, according to Citi. While the plan looks sensible, Sanofi needs to show it is rebuilding its pipeline for shares to recover, the analysts add. Shares fall 0.4%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 27, 2026 05:19 ET (09:19 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630361313?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 17:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630361313","market":"sg","top_or_hot":-1,"title":"Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0919 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s incoming CEO Belen Garijo needs to be clear on her strategic priorities, as the French drugmaker still needs to rebuild its drug pipeline, Citi analysts say in a research note. The company aims to defend the exclusivity of its blockbuster anti-inflammatory drug Dupixent--jointly developed with Regeneron--beyond the U.S. compound patent expiration in March 2031, Citi says. It also aims to extend dosing and leverage its alliance with Regeneron to bring new drugs to market, the analysts say. <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> has flagged financial firepower of between 15 billion and 25 billion euros for acquisitions and dealmaking, according to Citi. While the plan looks sensible, Sanofi needs to show it is rebuilding its pipeline for shares to recover, the analysts add. Shares fall 0.4%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2026 05:19 ET (09:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's New CEO Needs to Be Clear on Strategy -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-27 17:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0919 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s incoming CEO Belen Garijo needs to be clear on her strategic priorities, as the French drugmaker still needs to rebuild its drug pipeline, Citi analysts say in a research note. The company aims to defend the exclusivity of its blockbuster anti-inflammatory drug Dupixent--jointly developed with Regeneron--beyond the U.S. compound patent expiration in March 2031, Citi says. It also aims to extend dosing and leverage its alliance with Regeneron to bring new drugs to market, the analysts say. <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> has flagged financial firepower of between 15 billion and 25 billion euros for acquisitions and dealmaking, according to Citi. While the plan looks sensible, Sanofi needs to show it is rebuilding its pipeline for shares to recover, the analysts add. Shares fall 0.4%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2026 05:19 ET (09:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2630361313","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630361313","pubTimestamp":1777281540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0919 GMT - Sanofi's incoming CEO Belen Garijo needs to be clear on her strategic priorities, as the French drugmaker still needs to rebuild its drug pipeline, Citi analysts say in a research note. The company aims to defend the exclusivity of its blockbuster anti-inflammatory drug Dupixent--jointly developed with Regeneron--beyond the U.S. compound patent expiration in March 2031, Citi says. It also aims to extend dosing and leverage its alliance with Regeneron to bring new drugs to market, the analysts say. Sanofi has flagged financial firepower of between 15 billion and 25 billion euros for acquisitions and dealmaking, according to Citi. While the plan looks sensible, Sanofi needs to show it is rebuilding its pipeline for shares to recover, the analysts add. Shares fall 0.4%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4007":"制药","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SNYNF":"Sanofi","BK4588":"碎股","SNY":"赛诺菲安万特"},"translate_title":"赛诺菲新任首席执行官需要明确战略——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9,"SNYNF":1.5},"content_text":"0919 GMT - Sanofi's incoming CEO Belen Garijo needs to be clear on her strategic priorities, as the French drugmaker still needs to rebuild its drug pipeline, Citi analysts say in a research note. The company aims to defend the exclusivity of its blockbuster anti-inflammatory drug Dupixent--jointly developed with Regeneron--beyond the U.S. compound patent expiration in March 2031, Citi says. It also aims to extend dosing and leverage its alliance with Regeneron to bring new drugs to market, the analysts say. Sanofi has flagged financial firepower of between 15 billion and 25 billion euros for acquisitions and dealmaking, according to Citi. While the plan looks sensible, Sanofi needs to show it is rebuilding its pipeline for shares to recover, the analysts add. Shares fall 0.4%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2026 05:19 ET (09:19 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630361313","isCrawlerRequest":true}